Log in to search using one of your social media accounts:


Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting

Presentations Highlight 24-Hour Serial Spirometry Subgroup Findings from Two Replicate Pivotal Phase 3 Studies; Improvements Observed in St. George's Respiratory Questionnaire and COPD Assessment Test Results DUBLIN and HERTFORDSHIRE, England and PITTS... Biopharmaceuticals Theravance Biopharma, Mylan, Revefenacin, COPD
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

More News: Chronic Obstructive Pulmonary | Pharmaceuticals | Respiratory Medicine | Spirometry | Study